Trem-1 inhibitor for use in the treatment of a subject suffering from a coronavirus infection

A method for treating coronavirus disease 2019 (COVID-19) caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof, said method comprising administering to the subject a triggering receptor expressed on myeloid cells-1 (TREM-1) inhibitor.

An in vitro method for identifying a subject suffering from coronavirus disease 2019 (COVID-19) caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptible to respond to a triggering receptor expressed on myeloid cells-1 (TREM-1) inhibitor, said method comprising:

• measuring the level of soluble TREM-1 (sTREM-1) in a biological sample from the subject;
• and
• comparing the level of sTREM-1 measured in the biological sample from the subject to a reference value.

An in vitro method for monitoring the effectiveness of a triggering receptor expressed on myeloid cells-1 (TREM-1) inhibitor administered to a subject suffering from coronavirus disease 2019 (COVID-19) caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), said method comprising:

• measuring the level of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in a biological sample from the subject;
• and
• comparing the level of sTREM-1 measured in the biological sample from the subject to a reference value.